세계의 아데노바이러스 신염 시장 보고서(2025년)

Adenosine Deaminase-Severe Combined Immunodeficiency Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

아데노바이러스 신염 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 이 기간의 주요 동향으로는 기술의 진보, 유전자 치료의 채용, 정부의 대처, 유전자 검사의 진보, 바이오 테크놀로지의 진보 등을 들 수 있습니다.

유전성 질환의 유병률 증가는 아데노바이러스 신염 시장의 성장을 가속할 것으로 예측됩니다. 진단 기술의 진보, 의식의 향상, 부모의 나이의 상승, 환경의 영향, 인구 증가 등의 요인이, 유전성 질환의 유병률의 상승에 기여하고 있습니다. 이에 따라 첨단 진단 기술과 표적 치료에 대한 수요가 높아지고 있습니다. 예를 들어, 2022년 12월 영국 정부 부처인 보건사회부(DHSC)가 발표한 보고서에 따르면 2022년 10월 기준 약 33,000건의 전장 게놈 염기서열 분석이 이루어졌으며, 평균 진단 수율은 32%, 특정 조건에서는 61%까지 상승했습니다.

아데노바이러스 신염 시장의 주요 기업은 환자의 예후를 개선하고 생존율을 향상시키고 선진 의료 기술을 사용하여 질병의 근본적인 유전적 원인을 다루기 위해 유전자 치료와 같은 혁신적인 치료의 개발을 우선하고 있습니다. 사본을 도입하여 유전적 결함을 수정하는 것을 목표로 하며, 이 드문 경우에 생명을 위협하는 면역 질환을 장기적으로 치유할 가능성이 있습니다. 예를 들어, 2022년 5월 미국의 생명과학 및 진단 회사인 다나허 코퍼레이션은 AMP(Accelerating Medicines Partnership) 프로그램의 일환으로 맞춤형 유전자 치료 컨소시엄(BGTC)에 가입했습니다. 이 이니셔티브는 미국 식품 의약국(FDA), 미국 국립 위생 연구소(NIH), 제약 회사, 비영리 단체와 협력하여 희귀질환에 대한 맞춤형 유전자 치료 전진시키고 그 개발을 합리화하는 것을 목표로 하고 있습니다. 이 공동 연구는 유병률이 낮기 때문에 상업적인 관심이 한정되는 경향이 있는 희귀질환에 대한 종래의 의약품 개발의 과제에 임하는 것으로, 특히 중요합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 아데노바이러스 신염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 아데노바이러스 신염 시장 : 성장률 분석
• 세계의 아데노바이러스 신염 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 아데노바이러스 신염 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 아데노바이러스 신염 전체 시장(TAM)

제6장 시장 세분화

• 세계의 아데노바이러스 신염 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 효소 대체 요법(ERT)
• 유전자 치료
• 줄기세포 이식
• 지지 요법 치료
• 세계의 아데노바이러스 신염 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 정맥주사
• 피하
• 경구
• 세계의 아데노바이러스 신염 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 소아(유아 및 소아)
• 성인
• 세계의 아데노바이러스 신염 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 아데노바이러스 신염 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 전문 클리닉
• 연구기관
• 기타 최종 사용자
• 세계의 아데노바이러스 신염 시장 : 효소 대체 요법(ERT) 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 아데노신 데아미나제 효소 대체제
• 페길호 ㅏ에리스로포이에틴(PEG-EPO)
• 세계의 아데노바이러스 신염 시장 : 유전자 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 자가 줄기 세포 기반 유전자 치료
• 바이러스 벡터 매개 유전자 치료
• 세계의 아데노바이러스 신염 시장 : 줄기세포 이식 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• HLA 일치 골수 이식
• 제대혈 이식
• 세계의 아데노바이러스 신염 시장 : 지지 요법 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 항균 치료
• 면역 체계 지원
• 영양 지원

제7장 지역별/국가별 분석

• 세계의 아데노바이러스 신염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 아데노바이러스 신염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 아데노바이러스 신염 시장 : 경쟁 구도
• 아데노바이러스 신염 시장 : 기업 프로파일
  • Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • GlaxoSmithKline plc(GSK)개요, 제품 및 서비스, 전략 및 재무 분석
  • Astellas Pharma 개요, 제품 및 서비스, 전략 및 재무 분석
  • Orient EuroPharma 개요, 제품 및 서비스, 전략 및 재무 분석
  • Charles River Laboratories 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Chiesi Farmaceutici SpA
• Spark Therapeutics
• Rocket Pharmaceuticals
• Bluebird Bio
• Ospedale San Raffaele(OSR)
• Oxford Biomedica PLC
• Teijin Pharma
• Leadiant Biosciences
• Orchard Therapeutics PLC
• Fondazione Telethon
• Mustang Bio Inc
• Sigma-Tau Pharmaceuticals
• Shenzhen Geno-Immune Medical Institute
• ENZON Pharmaceuticals
• QED Bioscience Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 아데노바이러스 신염 시장(2029년) : 새로운 기회를 제공하는 국가
• 아데노바이러스 신염 시장(2029년) : 새로운 기회를 제공하는 부문
• 아데노바이러스 신염 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare genetic disorder caused by a deficiency of the enzyme adenosine deaminase, resulting in the toxic accumulation of metabolites that hinder immune cell development. Understanding ADA-SCID is crucial for early diagnosis and management to prevent life-threatening infections and complications.

The primary treatment options for ADA-SCID include enzyme replacement therapy (ERT), gene therapy, stem cell transplantation, and supportive care. ERT involves administering synthetic or recombinant enzymes to compensate for the deficient or absent enzyme in individuals with genetic disorders. These therapies are delivered through various routes, including intravenous, subcutaneous, and oral administration. Designed for both pediatric and adult patients, they are distributed through hospital, retail, and online pharmacies. Key end-users include hospitals, specialty clinics, research institutes, and other healthcare facilities.

The adenosine deaminase-severe combined immunodeficiency market research report is one of a series of new reports from The Business Research Company that provides adenosine deaminase-severe combined immunodeficiency market statistics, including the adenosine deaminase-severe combined immunodeficiency industry global market size, regional shares, competitors with the adenosine deaminase-severe combined immunodeficiency market share, detailed adenosine deaminase-severe combined immunodeficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the adenosine deaminase-severe combined immunodeficiency industry. This adenosine deaminase-severe combined immunodeficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adenosine deaminase-severe combined immunodeficiency market size has grown strongly in recent years. It will grow from $5.57 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising prevalence of severe combined immunodeficiency, an increasing incidence of primary immunodeficiencies (PID), a growing burden of immunodeficiency disorders, higher healthcare investments, and greater awareness of immunodeficiencies.

The adenosine deaminase-severe combined immunodeficiency market size is expected to see strong growth in the next few years. It will grow to $7.70 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be driven by the rising prevalence of genetic disorders, increased use of bone marrow transplantation, growing demand for non-conditioned stem cell transplantation, a higher prevalence of ADA deficiency, and a rising number of adenosine deaminase deficiency (PDA) cases. Key trends in this period include technological advancements, the adoption of gene therapy, government initiatives, advancements in genetic testing, and progress in biotechnology.

The increasing prevalence of genetic disorders is expected to drive the growth of the adenosine deaminase-severe combined immunodeficiency (ADA-SCID) market. Genetic disorders result from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Factors such as advancements in diagnostic technologies, greater awareness, higher parental age, environmental influences, and population growth contribute to the rising prevalence of genetic conditions. In particular, the increasing occurrence of genetic disorders, including ADA-SCID, is fueling the demand for advanced diagnostic techniques and targeted treatments. For example, in December 2022, a report published by the Department of Health & Social Care (DHSC), a UK-based government department, revealed that as of October 2022, approximately 33,000 whole genome equivalents had been sequenced, with an average diagnostic yield of 32%, rising to 61% in specific conditions. Consequently, the growing prevalence of genetic disorders is propelling the expansion of the ADA-SCID market.

Leading companies in the ADA-SCID market are prioritizing the development of innovative treatments, such as gene therapy, to improve patient outcomes, enhance survival rates, and address the underlying genetic causes of the disorder using advanced medical technologies. Gene therapy for ADA-SCID aims to correct the genetic defect by introducing a functional copy of the ADA gene, potentially offering a long-term cure for this rare and life-threatening immune condition. For instance, in May 2022, Danaher Corporation, a US-based life sciences and diagnostics company, joined the Bespoke Gene Therapy Consortium (BGTC) as part of the Accelerating Medicines Partnership (AMP) program. This initiative, in collaboration with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical companies, and non-profit organizations, seeks to advance customized gene therapies for rare diseases and streamline their development. This collaboration is particularly important as it addresses the challenges of traditional drug development for rare diseases, which often receive limited commercial interest due to their low prevalence.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc. for an undisclosed amount. This acquisition enhances Kyowa Kirin's focus on developing innovative treatments for rare and complex diseases by leveraging Orchard Therapeutics' expertise in gene therapy. Orchard Therapeutics plc, a UK-based company, specializes in creating gene therapies for rare genetic disorders.

Major players in the adenosine deaminase-severe combined immunodeficiency market are Novartis AG, GlaxoSmithKline plc (GSK), Astellas Pharma, Orient EuroPharma, Charles River Laboratories, Chiesi Farmaceutici S.p.A., Spark Therapeutics, Rocket Pharmaceuticals, Bluebird Bio, Ospedale San Raffaele (OSR), Oxford Biomedica PLC, Teijin Pharma, Leadiant Biosciences, Orchard Therapeutics PLC, Fondazione Telethon, Mustang Bio Inc., Sigma-Tau Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, ENZON Pharmaceuticals, and QED Bioscience Inc.

North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in adenosine deaminase-severe combined immunodeficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adenosine deaminase-severe combined immunodeficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adenosine deaminase-severe combined immunodeficiency market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, therapy services, and consultation & genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine deaminase-severe combined immunodeficiency market also includes sales of diagnostic tools, supportive therapies, and genetic testing kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adenosine Deaminase-Severe Combined Immunodeficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adenosine deaminase-severe combined immunodeficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adenosine deaminase-severe combined immunodeficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adenosine deaminase-severe combined immunodeficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Enzyme Replacement Therapy (ERT); Gene Therapy; Stem Cell Transplantation; Supportive Care Treatments
• 2) By Route of Administration: Intravenous; Subcutaneous; Oral
• 3) By Age Group: Pediatric (Infants and Children); Adults
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Others End-Users
• Subsegments:
• 1) By Enzyme Replacement Therapy (ERT): Adenosine Deaminase Enzyme Replacement; Pegylated Erythropoietin (PEG-EPO)
• 2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy; Viral Vector-Mediated Gene Therapy
• 3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant; Umbilical Cord Blood Transplant
• 4) By Supportive Care Treatments: Antimicrobial Therapy; Immune System Support; Nutritional Support
• Companies Mentioned: Novartis AG; GlaxoSmithKline plc (GSK); Astellas Pharma; Orient EuroPharma; Charles River Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adenosine Deaminase-Severe Combined Immunodeficiency Market Characteristics

3. Adenosine Deaminase-Severe Combined Immunodeficiency Market Trends And Strategies

4. Adenosine Deaminase-Severe Combined Immunodeficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Growth Rate Analysis
• 5.4. Global Adenosine Deaminase-Severe Combined Immunodeficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adenosine Deaminase-Severe Combined Immunodeficiency Total Addressable Market (TAM)

6. Adenosine Deaminase-Severe Combined Immunodeficiency Market Segmentation

• 6.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy (ERT)
• Gene Therapy
• Stem Cell Transplantation
• Supportive Care Treatments
• 6.2. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.3. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric (Infants and Children)
• Adults
• 6.4. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutes
• Others End-User
• 6.6. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Enzyme Replacement Therapy (ERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenosine Deaminase Enzyme Replacement
• Pegylated Erythropoietin (PEG-EPO)
• 6.7. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell-Based Gene Therapy
• Viral Vector-Mediated Gene Therapy
• 6.8. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Stem Cell Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HLA-Matched Bone Marrow Transplant
• Umbilical Cord Blood Transplant
• 6.9. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Supportive Care Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antimicrobial Therapy
• Immune System Support
• Nutritional Support

7. Adenosine Deaminase-Severe Combined Immunodeficiency Market Regional And Country Analysis

• 7.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 8.1. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 9.1. China Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 9.2. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 10.1. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 11.1. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 11.2. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 12.1. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 13.1. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 14.1. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 14.2. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 15.1. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 15.2. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 16.1. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 17.1. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 18.1. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 19.1. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 20.1. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 21.1. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 21.2. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 22.1. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 23.1. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 23.2. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 24.1. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 24.2. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 25.1. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 25.2. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 26.1. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 26.2. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 27.1. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 28.1. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 28.2. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market

• 29.1. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
• 29.2. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape And Company Profiles

• 30.1. Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape
• 30.2. Adenosine Deaminase-Severe Combined Immunodeficiency Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc (GSK) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Astellas Pharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Orient EuroPharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Charles River Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Adenosine Deaminase-Severe Combined Immunodeficiency Market Other Major And Innovative Companies

• 31.1. Chiesi Farmaceutici S.p.A.
• 31.2. Spark Therapeutics
• 31.3. Rocket Pharmaceuticals
• 31.4. Bluebird Bio
• 31.5. Ospedale San Raffaele (OSR)
• 31.6. Oxford Biomedica PLC
• 31.7. Teijin Pharma
• 31.8. Leadiant Biosciences
• 31.9. Orchard Therapeutics PLC
• 31.10. Fondazione Telethon
• 31.11. Mustang Bio Inc
• 31.12. Sigma-Tau Pharmaceuticals
• 31.13. Shenzhen Geno-Immune Medical Institute
• 31.14. ENZON Pharmaceuticals
• 31.15. QED Bioscience Inc.

32. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adenosine Deaminase-Severe Combined Immunodeficiency Market

34. Recent Developments In The Adenosine Deaminase-Severe Combined Immunodeficiency Market

35. Adenosine Deaminase-Severe Combined Immunodeficiency Market High Potential Countries, Segments and Strategies

• 35.1 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료